Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Biochem Genet. 2020 Jun;58(3):359-383. doi: 10.1007/s10528-020-09948-z. Epub 2020 Jan 29.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Although in recent years there has been a significant progress in the diagnosis, treatment, and prognosis of CVD, but due to their complex pathobiology, developing novel biomarkers and therapeutic interventions are still in need. MicroRNAs (miRNAs) are a fraction of non-coding RNAs that act as micro-regulators of gene expression. Mounting evidences over the last decade confirmed that microRNAs were deregulated in several CVDs and manipulating their expression could affect homeostasis, differentiation, and function of cardiovascular system. Here, we review the current knowledge concerning the roles of miRNAs in cardiovascular diseases with more details on cardiac remodeling, arrhythmias, and atherosclerosis. In addition, we discuss the latest findings on the potential therapeutic applications of miRNAs in cardiovascular diseases.
心血管疾病（CVDs）是全球发病率和死亡率的主要原因。尽管近年来在 CVD 的诊断、治疗和预后方面取得了重大进展，但由于其复杂的病理生物学，仍然需要开发新的生物标志物和治疗干预措施。microRNAs（miRNAs）是一类非编码 RNA，作为基因表达的微调节剂。过去十年中的大量证据证实，几种 CVD 中存在 microRNAs 的失调，并且操纵它们的表达可以影响心血管系统的内稳态、分化和功能。在这里，我们详细回顾了 miRNAs 在心脏重构、心律失常和动脉粥样硬化等心血管疾病中的作用的最新知识。此外，我们还讨论了 miRNAs 在心血管疾病中的潜在治疗应用的最新发现。
Biochem Genet. 2020-6
Acta Pharmacol Sin. 2018-6-7
Curr Drug Targets. 2017
Cardiovasc Pathol. 2020-10-3
Balkan Med J. 2020-2-5
Eur Rev Med Pharmacol Sci. 2019-3
Heart Lung Circ. 2014-6
J Mol Med (Berl). 2023-5
Arq Bras Cardiol. 2018-11
Iran J Public Health. 2022-5
Genes (Basel). 2022-8-26
Mol Biol Rep. 2022-10
Biomedicines. 2022-5-30
Front Cardiovasc Med. 2021-1-20
Zotero 插件